FDA Expands Evolocumab to Treat Adults at Increased Risk for Major Adverse Cardiovascular Events - Prabadin Corp

https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

FDA Expands Evolocumab to Treat Adults at Increased Risk for Major Adverse Cardiovascular Events

Health

August 25, 2025

By AdminPrabadin - 1 week ago

0

Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).

administrator